Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants

Objective This study aimed to determine the association between daily fluid intake and the duration of hemodynamically significant patent ductus arteriosus (hsPDA). Methods This is a retrospective cohort study of extremely preterm infants (<29 weeks) admitted in the Neonatal Intensive Care Unit of the Advent Health for Children from January 2013 to March 2016, if hsPDA was diagnosed in first week of life and serial echocardiograms were available. Diagnosis of hsPDA was based on a scoring system and its duration was estimated from serial echocardiograms. Cohort was divided into two groups based on duration of hsPDA (<1week, group A and ≥1 week, group B). Daily fluid intake was categorized as prescribed and actual. Prescribed volume was ordered by clinicians based on birth weight, not including trophic feeds, intravenous (IV) boluses or transfusions, etc. Actual intake was calculated by the electronic medical records based on daily weights and included all enteral or parenteral fluids. Multivariate analysis was performed to determine an association between total daily fluid intake over the first week of life and the duration of hsPDA. Two groups were compared to observe the difference between prescribed and actual daily fluid intakes. Results We enrolled 50 infants in group A and 76 in group B. Infants in group B were of significantly lower gestation and required prolonged ventilation and hospitalization. An association between higher fluid intake in the first 2 days of life and prolonged duration of hsPDA was confirmed by multivariate analysis. Actual fluid intake was significantly higher than prescribed total fluid intake in first 4 days of life for infants in both groups. Conclusion In extremely preterm infants, higher fluid intake in first 2 days of life is associated with prolonged duration of hsPDA. Actual daily fluid intake can be significantly higher than prescribed daily fluids due to daily weight changes and additional fluid administration. Key Points

Download Full-text

Conservative Non-intervention Approach for Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants

Frontiers in Pediatrics ◽

10.3389/fped.2020.605134 ◽

2020 ◽

Vol 8 ◽

Author(s):

Se In Sung ◽

Yun Sil Chang ◽

So Yoon Ahn ◽

Heui Seung Jo ◽

Misun Yang ◽

...

Keyword(s):

Patent Ductus Arteriosus ◽

Preterm Infants ◽

Necrotizing Enterocolitis ◽

Ductus Arteriosus ◽

Intervention Approach ◽

Extremely Preterm ◽

Extremely Preterm Infants ◽

Surgical Treatments ◽

Minimal Evidence ◽

Patent Ductus

While persistent patent ductus arteriosus (PDA) in preterm infants has been known to be associated with increased mortality and morbidities including bronchopulmonary dysplasia, and necrotizing enterocolitis, there is minimal evidence supporting their causal relationships, and most traditional medical and/or surgical treatments have failed to show improvements in these outcomes. As such, the pendulum has swung toward the conservative non-intervention approach for the management of persistent PDA during the last decade; however, the benefits and risks of this approach are unclear. In this mini review, we focused on whom, when, and how to apply the conservative non-intervention approach for persistent PDA, especially in extremely preterm infants.

Download Full-text

Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants

Journal of Perinatology ◽

10.1038/s41372-019-0496-5 ◽

2019 ◽

Vol 39 (12) ◽

pp. 1648-1655 ◽

Cited By ~ 6

Author(s):

Hussnain Mirza ◽

Jorge Garcia ◽

Genevieve McKinley ◽

Laura Hubbard ◽

Wendla Sensing ◽

...

Keyword(s):

Patent Ductus Arteriosus ◽

Preterm Infants ◽

Bronchopulmonary Dysplasia ◽

Ductus Arteriosus ◽

Extremely Preterm ◽

Extremely Preterm Infants ◽

Patent Ductus

Download Full-text

Timing of Pharmacological Treatment for Patent Ductus Arteriosus and Risk of Secondary Surgery, Death or Bronchopulmonary Dysplasia: A Population-Based Cohort Study of Extremely Preterm Infants

Neonatology ◽

10.1159/000367887 ◽

2014 ◽

Vol 107 (2) ◽

pp. 87-92 ◽

Cited By ~ 19

Author(s):

Anna Gudmundsdottir ◽

Stefan Johansson ◽

Stellan Håkansson ◽

Mikael Norman ◽

Karin Källen ◽

...

Keyword(s):

Cohort Study ◽

Patent Ductus Arteriosus ◽

Preterm Infants ◽

Pharmacological Treatment ◽

Ductus Arteriosus ◽

Population Based ◽

Secondary Surgery ◽

Extremely Preterm ◽

Extremely Preterm Infants ◽

Patent Ductus

Download Full-text

Early haemodynamically significant patent ductus arteriosus does not predict future persistence in extremely preterm infants

Acta Paediatrica ◽

10.1111/apa.14752 ◽

2019 ◽

Vol 108 (9) ◽

pp. 1590-1596

Author(s):

Karl Wilhelm Olsson ◽

Anders Jonzon ◽

Richard Sindelar

Keyword(s):

Patent Ductus Arteriosus ◽

Preterm Infants ◽

Ductus Arteriosus ◽

Extremely Preterm ◽

Extremely Preterm Infants ◽

Patent Ductus

Download Full-text

Changes in Serum Creatinine Levels and Natural Evolution of Acute Kidney Injury with Conservative Management of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants at 23–26 Weeks of Gestation

Journal of Clinical Medicine ◽

10.3390/jcm9030699 ◽

2020 ◽

Vol 9 (3) ◽

pp. 699 ◽

Cited By ~ 2

Author(s):

Eun Seo ◽

Se Sung ◽

So Ahn ◽

Yun Chang ◽

Won Park

Keyword(s):

Acute Kidney Injury ◽

Patent Ductus Arteriosus ◽

Serum Creatinine ◽

Preterm Infants ◽

Ductus Arteriosus ◽

Kidney Injury ◽

Adverse Outcomes ◽

Extremely Preterm ◽

Extremely Preterm Infants ◽

Patent Ductus

Changes in kidney function in extremely preterm infants (EPT) with conservatively managed hemodynamically significant (HS) patent ductus arteriosus (PDA) are not known well. We aimed to present the postnatal course in serum creatinine levels (sCr), prevalence of acute kidney injury (AKI), then relevance between AKI and adverse outcomes in EPT with conservatively managed HS PDA. By review of medical records, we analyzed the postnatal course of sCr and prevalence of stage 3 AKI defined by the modified Kidney Disease Improving Global Outcome (KDIGO) in EPT at gestational age of 23 to 26 weeks with conservatively treated HS PDA. We investigated if the presence and/or prolonged duration of stage 3 AKI elevated the risk of adverse outcomes. The results showed that, neither factor was associated with adverse outcomes. While the average PDA closure date was at postnatal day (P) 41 and 53, sCr peaked at P 10 and 14 and the cumulative prevalence of stage 3 AKI was 57% and 72% in the EPT of 25–26 and 23–24 weeks’ gestation, respectively. The high prevalence of stage 3 AKI without adverse outcomes in EPT with conservatively managed HS PDA suggests that it might reflect renal immaturity rather than pathologic conditions.

Download Full-text